Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945000 | 0.91 | SRD5A2 (0.55) | SRD5A2HSD17B1HSD17B2NR1H2MCL1 | |
| SCHEMBL18002342 | 0.84 | SRD5A2 (0.45) | SRD5A2HSD17B1HSD17B2HDAC6NR1H2 | |
| SCHEMBL21944798 | 0.81 | NR4A2 (0.45) | LMNAPKMHSD17B10MAOB | |
| SCHEMBL18005567 | 0.77 | NR1H2 (0.39) | SRD5A2HSD17B1HSD17B2HDAC6NR1H2 | |
| SCHEMBL28876730 | 0.74 | SRD5A2 (0.44) | SRD5A2NR1H2LMNAPKMHSD17B10 | |
| SCHEMBL18002480 | 0.74 | SRD5A2 (0.52) | SRD5A2NR1H2NR1H3SRD5A1MAOB | |
| SCHEMBL28320645 | 0.73 | SRD5A2 (0.43) | SRD5A2NR1H2LMNAPKMHSD17B10 | |
| SCHEMBL28320545 | 0.73 | IDO1 (0.58) | SRD5A2NR1H2 | |
| SCHEMBL16399041 | 0.73 | SRD5A2 (0.43) | SRD5A2NR1H2MCL1LMNAPKM | |
| SCHEMBL21945004 | 0.72 | SRD5A2 (0.43) | SRD5A2NR1H2MCL1NR1H3SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | SRD5A2 937/4885HSD17B1 265/4885HSD17B2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.